Idarubicin HCl (Synonyms: 4Demethoxydaunorubicin, 4DMD, NSC 256439) |
| カタログ番号GC14969 |
イダルビシン HCl は、アントラサイクリン系抗白血病薬です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 57852-57-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Idarubicin HCl is an orally active anthracycline antileukemic agent [1]. Idarubicin HCl stabilizes the complex between topoisomerase II and DNA, preventing DNA repair and normal replication. This ultimately leads to accumulation of DNA breaks, replication arrest, and induction of cell cycle arrest and apoptosis [2-3]. Idarubicin HCl is primarily used to treat adult acute myeloid leukemia [4].
In T47D cells, the cell viability of cells was significantly reduced after Idarubicin HCl (0.1-10μM;24-72h) treatment [5]. In fibroblasts, Idarubicin HCl (0.5-10μM; 24h) induces a time-dependent decrease in mitochondrial membrane potential and significantly increases intracellular calcium concentration and caspase-3 activity [6].
In U937 cells xenograft mice model, combination of decitabine and Idarubicin HCl (0.5mg/kg; ip; 7d) effectively inhibits tumor growth [7]. In LNCaP cells xenograft mice model, Idarubicin HCl (0.25mg/kg; ip; 25d) alone or in combination with abiraterone acetate significantly reduced tumor growth and prolonged mouse survival [8].
References:
[1]. Orlandi P, Barbara C, Bocci G, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids[J]. Journal of chemotherapy, 2005, 17(6): 663-667.
[2]. Dartsch D C, Gieseler F. Repair of idarubicin-induced DNA damage: a cause of resistance?[J]. DNA repair, 2007, 6(11): 1618-1628.
[3]. van den Boogaard W M C, Komninos D S J, Vermeij W P. Chemotherapy side-effects: not all DNA damage is equal[J]. Cancers, 2022, 14(3): 627.
[4]. Sherif H A, Magdy A, Elshesheni H A, et al. Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia[J]. Leukemia Research Reports, 2021, 16: 100272.
[5]. Zhong S, Li C, Han X, et al. Idarubicin stimulates cell cycle-and TET2-dependent oxidation of DNA 5-methylcytosine in cancer cells[J]. Chemical Research in Toxicology, 2019, 32(5): 861-868.
[6]. Dragojew S, Marczak A, Maszewski J, et al. The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts[J]. Cellular & molecular biology letters, 2008, 13(2): 182-194.
[7]. Li K, Hu C, Mei C, et al. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target[J]. Journal of translational medicine, 2014, 12(1): 167.
[8]. Zhang Y, Wei W, Li C, et al. Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein[J]. Cell Death & Disease, 2022, 13(12): 1034.
| Cell experiment [1]: | |
Cell lines | T47D cells |
Preparation Method | Human breast cancer cell line T47D was cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum, 100U/mL penicillin, and 100μg/mL streptomycin in a humidified incubator at 37℃ and 5% CO2. When the cell confluence reached approximately 70%, fresh medium containing a certain concentration of Idarubicin HCl was used to continue culturing for 24 hours or longer. After a period of Idarubicin HCl treatment, cells were collected for genomic DNA extraction. |
Reaction Conditions | 0.1-10μM;24-72h |
Applications | The cell viability of cells was significantly reduced after Idarubicin HCl treatment. |
| Animal experiment [2]: | |
Animal models | U937 cells xenograft mice model |
Preparation Method | The AML cell line U937 (1 × 107 cells/animal) was injected subcutaneously into the right flank of 6- to 8-week-old NOD-SCID mice. When tumors reached a volume of ~50 mm3, the animals were randomly divided into four groups. A total of 16 mice were divided into four groups of 4. Five consecutive days of decitabine (0.5mg/kg/day) were followed by three days of Idarubicin HCl (0.5mg/kg/day), or five days of decitabine alone followed by three days of Idarubicin HCl alone. An untreated control group received PBS. Drug and PBS were injected intraperitoneally. |
Dosage form | 0.5mg/kg; ip; 7d |
Applications | Combination of decitabine and Idarubicin HCl effectively inhibits tumor growth. |
References: | |
| Cas No. | 57852-57-0 | SDF | |
| 同義語 | 4Demethoxydaunorubicin, 4DMD, NSC 256439 | ||
| Chemical Name | 9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride | ||
| Canonical SMILES | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl | ||
| Formula | C26H27NO9.HCl | M.Wt | 533.95 |
| 溶解度 | ≥ 26.7mg/mL in DMSO | Storage | 4°C, away from moisture and light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8728 mL | 9.3642 mL | 18.7283 mL |
| 5 mM | 374.6 μL | 1.8728 mL | 3.7457 mL |
| 10 mM | 187.3 μL | 936.4 μL | 1.8728 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *